Patient-specific myeloma idiotype peptide-MHC class II complex (Id-MHC II complex)

Patient-specific myeloma idiotype peptides presented on MHC class II of autologous dendritic cells represent a personalized immunotherapy target for the treatment of multiple myeloma [1]. The idiotype (Id) refers to the unique antigenic determinants located within the variable regions of the monoclonal immunoglobulin (M-protein) produced by a patient's malignant plasma cells, serving as a highly specific tumor neoantigen [2]. In this therapeutic approach, autologous dendritic cells (DCs) are loaded with these patient-specific Id-peptides to be presented via MHC class II molecules to the immune system [3]. This presentation is designed to prime CD4+ T-helper cells, which are essential for orchestrating a robust and sustained anti-tumor immune response, including the activation of CD8+ cytotoxic T-lymphocytes [4]. By targeting the unique signature of the cancerous clone, this strategy aims to achieve high specificity and long-term immune surveillance while minimizing damage to healthy B-cells and other tissues [5]. (Citations: [1] Liso, A., et al. (2000) Blood; [2] Yi, Q., et al. (1997) Journal of Experimental Medicine; [3] Reichardt, V. L., et al. (2003) Blood; [4] Brossart, P., et al. (2000) Blood; [5] Wen, Y. J., et al. (1998) Clinical Cancer Research).

Other names

Myeloma idiotype-pulsed dendritic cellsId-DC vaccine targetTumor-specific idiotype antigenPersonalized myeloma neoantigenMHC II-restricted idiotype peptide

Induction of a patient-specific cellular immune response by presenting tumor-derived idiotype peptides to T-cells via MHC class II molecules on autologous dendritic cells, leading to the activation of CD4+ helper T-cells and subsequent recruitment of cytotoxic T-lymphocytes to eliminate malignant plasma cells.